Wireless Video Doorbell,Smart Wireless Video Doorbell Made In China,720P 1080P Wireless Video Doorbell, Wireless Video Doorbell With Batteries,Wireless Video Doorbell Villa Zhuhai Mingke Electronics Technology Co., Ltd , https://www.mingke-tech.com
Breast cancer is the most common malignancy in women. About 1.4 million women worldwide suffer from breast cancer every year, and 400,000 women die of breast cancer. In recent years, the incidence of breast cancer in China has risen rapidly. There are about 200,000 new breast cancer patients every year. In some big cities and coastal cities, breast cancer is the first malignant tumor among women, and it has become a female patient. The enemy of health.
The incidence of breast cancer has increased year by year, but the mortality rate has not increased correspondingly, which is due to the rational application of early diagnosis of breast cancer and adjuvant treatment for postoperative prevention of recurrence and metastasis. Among them, as the traditional treatment of breast cancer, as new drugs are not available, the status of adjuvant chemotherapy is still important.
1. All breast cancer patients need adjuvant chemotherapy after surgery
For a long time, the main treatment for early breast cancer was surgery. Due to advances in surgery, although the local control rate of the tumor has been greatly improved, many patients eventually die from distant metastasis. With the further study of breast cancer, it is found that there is recessive metastasis in early breast cancer, and breast cancer may be a systemic disease. This discovery has promoted the rise and progress of modern systemic adjuvant chemotherapy.
Whether it was the CMF program of the 1970s, the anthracycline-based program of the 1980s, or the taxane-containing regimen of the 1990s, the results of the study showed that for most breast cancers, especially those with positive lymph nodes. In addition, postoperative adjuvant chemotherapy can improve the survival rate of patients.
However, not all patients require chemotherapy, especially for node-negative, hormone receptor-positive. In patients, the results of 21 genes showed that only patients with high risk of recurrence can benefit from chemotherapy; for low-risk patients, endocrine therapy can be given.
2. Dosage and treatment are not enough
We often see in the clinic that although the patient received postoperative adjuvant chemotherapy, the dose was significantly lower or the chemotherapy cycle was less. For example, the standard dose of doxorubicin should be about 50 mg/m2, and the minimum should not be less than 40 mg/m2; the dose of epirubicin is generally 75-100 mg/m2. Reducing the dose may reduce the efficacy. Another common phenomenon is insufficient chemotherapy cycles and endocrine therapy. Sometimes chemotherapy is stopped only for 2 to 3 cycles of chemotherapy, and some patients are only discontinued after 2 to 3 years of endocrine therapy.
3. Overtreatment
As with under-treatment, over-treatment is also very harmful. The results of Italian scholars show that 12-cycle CMF is not superior to 6-cycle CMF, but increases the incidence of adverse reactions. In recent years, the results of gene microarray research can be used to guide individualized treatment of breast cancer, and also help to avoid over-treatment.
4. Choose improper medicine
Improper drug selection is also a common mistake in postoperative adjuvant chemotherapy. We know that postoperative adjuvant therapy is different from the treatment of advanced patients, and short-term effects are not seen, but long-term effects can only be observed by follow-up. Therefore, the choice of the program can only be based on the results of large-scale randomized clinical trials, and can not be subjectively determined, and drugs and programs that have not been clinically proven can not be applied to the adjuvant treatment of breast cancer. Foreign breast cancer clinical treatment guidelines release treatment guidelines based on evidence-based medical research results every year or years to guide the standard treatment of breasts, and domestic work in this area is quite lagging.
5. Feel free to change the plan
It is not appropriate because the patient has some toxic side effects or other reasons during the treatment, which is not appropriate, because we do not know whether the new program is effective, even if the two programs are effective, but use Together, it does not necessarily increase the efficacy or even the harmful effects. A typical example is the use of epirubicin first, and the CMF regimen is significantly better than the first CMF regimen. If you change the plan at will, it can sometimes be counterproductive.
The goal of adjuvant chemotherapy for early breast cancer should be to seek cure, so the choice should emphasize the follow-up guidelines and standardize treatment behavior.
[China Pharmaceutical Network Health Health] Breast cancer is one of the biggest killers of women's health. In recent years, the prevalence of breast cancer is also rising. The etiology of breast cancer is not fully understood, but the rational application of early diagnosis of breast cancer and adjuvant treatment for postoperative prevention of recurrence and metastasis has resulted in a corresponding increase in mortality. In the adjuvant treatment of breast cancer, people still have the following five major misunderstandings.
(Recognize the five major misunderstandings of breast cancer adjuvant chemotherapy treatment behavior picture source: Baidu pictures)